Summary
This is a global, multicenter, open-label safety extension study. Participants receiving
single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with
other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and
receiving benefit at the closure of parent study are eligible for continued treatment in this
study.